Editas Medicine
EDIT
238 hedge funds and large institutions have $517M invested in Editas Medicine in 2023 Q2 according to their latest regulatory filings, with 42 funds opening new positions, 75 increasing their positions, 48 reducing their positions, and 39 closing their positions.
146% more capital inflows, than outflows
Capital inflows: $155M | Capital outflows: $62.8M
73% more call options, than puts
Call options by funds: $8.36M | Put options by funds: $4.84M
56% more repeat investments, than reductions
Existing positions increased: 75 | Existing positions reduced: 48
1.04% more ownership
Funds ownership: 76% → 77.04% (+1%)
8% more first-time investments, than exits
New positions opened: 42 | Existing positions closed: 39
1% more funds holding
Funds holding: 236 → 238 (+2)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Deep Track Capital
Greenwich,
Connecticut
|
+$30.1M |
| 2 |
Avidity Partners Management
Dallas,
Texas
|
+$26.1M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$24.7M |
| 4 |
Ghisallo Capital Management
Boston,
Massachusetts
|
+$8.49M |
| 5 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.39M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
-$13.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
-$11.2M |
| 3 |
PFM Health Sciences
San Francisco,
California
|
-$5.22M |
| 4 |
Bank of America
Charlotte,
North Carolina
|
-$4.48M |
| 5 |
Citigroup
New York
|
-$3.88M |
EDIT Hedge Fund Activity: Q2 2023 in Review
238 of the 6,389 institutional investors tracked by Wall St. Rank reported a position in Editas Medicine (EDIT) for Q2 2023, worth a combined $517M — up 35% from $384M a quarter earlier.
Buyers outnumbered sellers: 42 funds opened new EDIT positions and 39 closed out — a net gain of 3 holders — while 75 added to existing stakes and 48 trimmed.
The largest buyer was Deep Track Capital, opening a new position worth an estimated $30.1M. The largest seller was State Street, cutting an estimated $13.3M.
- 238 institutional investors held Editas Medicine (EDIT) as of Q2 2023, up from 236 in Q1 2023.
- Funds reported $517M of Editas Medicine stock for Q2 2023, up 35% quarter-over-quarter.
- 42 funds opened new Editas Medicine positions in Q2 2023 and 39 closed out, a net change of +3 holders.
- The largest Editas Medicine buyer in Q2 2023 was Deep Track Capital, an estimated $30.1M added.
- The largest Editas Medicine seller in Q2 2023 was State Street, an estimated $13.3M sold.
Based on aggregated 13F filings for Q2 2023.